Development of poly(ε-Caprolactone) scaffold loaded with simvastatin and beta-cyclodextrin modified hydroxyapatite inclusion complex for bone tissue engineering

4Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

© 2016 by the authors. In this study, we developed poly(ε-caprolactone) (PCL) 3D scaffolds using a solid free form fabrication (SFF) technique. β-cyclodextrin (βCD) was grafted to hydroxyapatite (HAp) and this βCD grafted HAp was coated onto the PCL scaffold surface, followed by drug loading through an inclusion complex interaction between the βCD and adamantane (AD) or between βCD and simvastatin (SIM). The scaffold structure was characterized by scanning electron microscopy (SEM). The release profile of simvastatin in the β-CD grafted HAp was also evaluated. Osteogenic differentiation of adipose-derived stromal cells (ADSCs) was examined using an alkaline phosphatase activity (ALP) assay. The results suggest that drug loaded PCL-HAp 3-D scaffolds enhances osteogenic differentiation of ADSCs.

Cite

CITATION STYLE

APA

Lee, J. B., Kim, J. E., Bae, M. S., Park, S. A., Balikov, D. A., Sung, H. J., … Kwon, I. K. (2016). Development of poly(ε-Caprolactone) scaffold loaded with simvastatin and beta-cyclodextrin modified hydroxyapatite inclusion complex for bone tissue engineering. Polymers, 8(2). https://doi.org/10.3390/polym8020049

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free